Healthcare

Popular Topics in Healthcare

Subscribe to Updates in Healthcare

By RSS

The Expertise Imperative and Compliance Technology: Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework

This page may include content provided by Council Members, your access to which is subject to the Terms of Use.

Find Out More

GLG News by Multiple Myeloma Physicians

Articles with lock require a subscription to GLG News |

Request a free trial

August 21, 2008

Cervical Cancer Vaccines: Hope or Hype?
Analysis of: Drug Makers’ Push Leads to Cancer Vaccines’ Fast Rise | www.nytimes.com
Author: GLG Expert Contributor

Cervical cancer vaccines manufactured by Merck and Glaxo have been hyped, pushed and if the companies have their way, mandated by various states and organizations. (Who is benefiting? Patients or the politicians?) There are many unanswered questions but marketing and mandates press on!

August 20, 2008

Sunitinib vs Interferon: No contest at the onset
Analysis of: Economic Evaluation of Sunitinib Malate for the First-Line Treatment of Metastatic Renal Cell Carcinoma | jco.ascopubs.org
Author: GLG Expert Contributor

When using a model (of whose desin?) Pfizer's Sunitinib (Sutent) was found to be cost effective by Pfizer people? Surprise!!!

August 19, 2008

Cole & Pfizer: Happy together in NSCLCA (non small cell lung cancer)
Analysis of: Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer | jco.ascopubs.org
Author: GLG Expert Contributor

"The investigator-assessed objective response rate (complete and partial response), including both confirmed and unconfirmed responses, was 38% in the PF-3512676 plus chemotherapy arm and 19% in the chemotherapy-alone arm (P = .043)." In other words. IT MAY WORK!

August 15, 2008
BiovaxID: Does It Work?
Analysis of: Biovest Reports Results for Patients Treated with Anti-Cancer Vaccine: BiovaxID(R) Demonstrates Clinically and Statistically Significant Improvement of Disease-Free Survival in Non-Hodgkin's Lymphoma in Pivotal Phase 3 Clinical Trial | biz.yahoo.com
Author: Donald Tsai, Assistant Professor of Medicine, University of Pennsylvania Cancer Center

1) BiovaxID shows a 100% improvement in DFS at 3 years (p=0.24) 2) BiovaxID shows an improvement in median overall DFS with a significant P value (p=0.047) 2) This is the first lymphoma vaccine with a suggestion of activity. 3) BiovaxID shows evidence of activity despite the failure of 2 other...

August 14, 2008
UK the model for US healthcare?
Analysis of: UK Says Kidney Cancer Drugs Are Too Pricey | www.pharmalot.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.

In this election year some have encouraged adoption of socialized medical services UK healthcare is an example of what some in this country have said we need to model our future healthcare system The recent use of biologics such as the TKIs have resulted in options for...

August 13, 2008

Hepcidine quantification is a valuable tool for iron balance analysis
Analysis of: UCLA And Biotech Company Develop First Blood Test To Measure Key Hormone That Regulates Iron | www.medicalnewstoday.com
Author: GLG Expert Contributor

Hepcidine is a key regulator of iron balence. Despite the availability of some iron makers (ferritin, sideremia and transferrin), hepcidine dosage can aid in the interpretation of complex clinical cases. However, its use could be limited to very particular clinical cases.

August 13, 2008

"Health-care costs are expected to rise more than 10% ".... and we can continue this for how long??
Analysis of: Insurers Expect Health-Care Costs To Rise More Than 10% Next Year | online.wsj.com
Author: GLG Expert Contributor

10% increase in medical spending when the overall cost of living is 1/2 of medical costs and we are happy??

August 11, 2008

Fair or Unfair Decision: the cost of the drugs for kidney cancer is more than the economy can bear.
Analysis of: UK Says Kidney Cancer Drugs Are Too Pricey | www.pharmalot.com
Author: GLG Expert Contributor

Pfizer’s Sutent, Wyeth’s Torisel, Bayer’s Nexavar and Avastin, sold by Roche and Genentech have been deemed too expensive to be paid for by UK agencies

August 7, 2008

Salmonella; Cancer cells?? Let's not get carried away
Analysis of: Salmonella Is Tested To Fight Cancer Cells | online.wsj.com
Author: GLG Expert Contributor

Salmonella targeting cancer cells? In humans???

August 6, 2008

Boy will this p.... off Urologists as well as AARP!
Analysis of: Panel Urges End to Prostate Screening at Age 75 | www.nytimes.com
Author: GLG Expert Contributor

Since treatment may be worse than the disease it is being recommended that routine prostate cancer screening be stopped after the age of 75.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 Next11 to 20 of 837

More GLG News in
Healthcare

GLG News: What Experts Think Is Important

Generated at 2008-09-06T17:45:17.377

GLG News by Multiple Myeloma Physicians

More GLG News inHealthcare

GLG News: What Experts Think Is Important

More GLG News in
Healthcare